Bethlehem-based Levolta Pharmaceuticals develops and commercializes reformulated medicines for rheumatology, immunology and cancer, with its lead investigational therapy VOLT01 aimed at osteoarthritis. The clinical-stage company uses a reformulation platform and 505(b)(2) regulatory pathway to improve existing therapies’ therapeutic profiles while reducing development timelines. In 2023, Levolta licensed VOLT01 commercialization in the Middle East and Africa to Tabuk Pharmaceuticals, while retaining responsibility for manufacturing and quality assurance initiatives.